COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,620 Articles (22,913 medRxiv, 8,707 bioRxiv)

Most recent first Previous |  Page 254: Articles 2531-2540  | Next

TMEM106B-mediated SARS-CoV-2 infection allows for robust ACE2-independent infection in vitro but not in vivo
Yan, K., Dumenil, T., Stewart, R., Bishop, C. R., Tang, B., Suhrbier, A., Rawle, D. J.
10.1101/2024.05.08.593110 — Posted: 2024-05-08
Genomic epidemiology of early SARS-CoV-2 transmission dynamics in Bangladesh
Carnegie, L., McCrone, J., Du Plessis, L., Hasan, M., Ali, M. Z., Begum, R., Hassan, M. Z., Islam, S., Rahman, M. H., Uddin, A., Sarker, M. S., Das, T., Hossain, M. M., Khan, M., Razu, M. H., Akram, A., Arina, S., Hoque, M. E., Molla, M. M. A., Nafisa, T., Angra, P., Rambaut, A., Pullan, S., Osman, K., Hoque, M. A., Biswas, P., Flora, M. S., Raghwani, J., Fournie, G., Samad, M. A., Hill, S. C.
10.1101/2024.05.07.24306987 — Posted: 2024-05-07
Mexicos surge of violence and COVID 19 drive life expectancy losses 2015 2021.
Zazueta-Borboa, J. D., Vazquez Castillo, P., Gargiulo, M., Aburto, J. M.
10.1101/2024.05.07.24306982 — Posted: 2024-05-07
Immunogenicity and Safety of Gamma, Omicron BA.4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: a Phase II/III, Randomized, Clinical Trial.
Perez-Marc, G., Coria, L. M., Ceballos, A., Rodriguez, J. M., Lombardo, M. E., Bruno, L., Paez Cordoba, F., Fascetto Cassero, C. G., Salvatori, M., Rios Medrano, M. A., Fulgenzi, F. R., Alzogaray, M. F., Mykietiuk, A., Uriarte, I. L., Itcovici, N., Smith Casabella, T. E., Corral, G., Bruno, M. E., Roldan, O., Nunez, S. A., Cahn, F., Bianchi, A., Braem, V. M., Christmann, A., Corradetti, S., Darraidou, M. C., Di Nunzio, L., Estrada, T. B., Lopez Castelo, R., Marchionatti, C. G., Pitocco, L., Trias Uriarte, V. M., Wood, C. J., Zadoff, R., Bues, F., Garrido, R. M., Laboratorio Pablo Cassara group
10.1101/2024.05.06.24306575 — Posted: 2024-05-06
Usefulness of ecological mobility and socio-economic indicators in SARS-CoV-2 infection modelling: a French case study
ROMAIN-SCELLE, N., RICHE, B., BENET, T., RABILLOUD, M.
10.1101/2024.05.05.24306895 — Posted: 2024-05-06
Factors affecting adoption of COVID-19 prevention measures among community members: A Case study of Entebbe Municipal council in Uganda.
Namanya, E., Margret, N. J., Mugenyi, N., Twineamatsiko, A.
10.1101/2024.05.04.24306856 — Posted: 2024-05-06
Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern
Rubio, A. A., Baharani, V. A., Dadonaite, B., Parada, M., Abernathy, M. E., Wang, Z., Lee, Y. E., Eso, M., Phung, J., Ramos, I., Chen, T., El Nesr, G., Bloom, J. D., Bieniasz, P. D., Nussenzweig, M. C., Barnes, C. O.
10.1101/2024.05.05.592584 — Posted: 2024-05-06
SCORE: Serologic Evidence of COVID-19, Social, and Occupational Contacts in Healthcare Workers in a Sample of Long-Term Care and Acute Care Facilities in Southeastern Ontario (SCORE)
MARTINEZ CAJAS, J. L., Alvarado, B. E., Jolly, A., Gong, Y., Stoner, B., Perez- Patrigeon, S., Evans, G., Guan, H.
10.1101/2024.05.03.24306818 — Posted: 2024-05-05
A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24
Nyame, P., Togami, A., Yoshida, T., Masunaga, T., Begum, M. M., Terasawa, H., Monde, N., Tahara, Y., Tanaka, R., Tanaka, Y., Kubi, J. A., Amesimeku, W. O., Hossain, M. J., Otsuka, M., Yoshimura, K., Ikeda, T., Sawa, T., Satou, Y., Fujita, M., Maeda, Y., Tateishi, H., Monde, K.
10.1101/2024.05.03.592399 — Posted: 2024-05-05
Oxidative Stress is a shared characteristic of ME/CFS and Long COVID
Shankar, V., Wilhelmy, J., Michael, B., Cervantes, L., Mallajosyula, V., Davis, R., Snyder, M., Younis, S., Robinson, W. H., Shankar, S., Mischel, P., Bonilla, H., Davis, M.
10.1101/2024.05.04.592477 — Posted: 2024-05-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).